tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cardiomegaly D006332 31 associated lipids
Liver Diseases D008107 31 associated lipids
Diarrhea D003967 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Uremia D014511 33 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Burns D002056 34 associated lipids
Cataract D002386 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Glomerulonephritis D005921 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Heart Failure D006333 36 associated lipids
Nervous System Diseases D009422 37 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Stratta RJ et al. Does surgical technique influence outcomes after simultaneous kidney-pancreas transplantation? 2004 Transplant. Proc. pmid:15194373
Mastrobuoni S et al. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience. 2007 Transplant. Proc. pmid:17889125
Jordan ML et al. Tacrolimus for rescue of refractory renal allograft rejection. 1998 Transplant. Proc. pmid:9636511
Kotowski M et al. The Importance of New Generation Sequencing (NGS) HLA Typing in Renal Transplantation-Preliminary Report. Transplant. Proc. pmid:29937294
Jun H et al. Experiences on conversion to once-daily Advagraf and sirolimus combination in stable kidney recipients. 2014 Transplant. Proc. pmid:24655973
Balda S et al. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid. 2009 Jul-Aug Transplant. Proc. pmid:19715841
Perrakis A et al. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome. 2011 Transplant. Proc. pmid:22172830
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. 1994 Transplant. Proc. pmid:7527960
Neuhaus PJ Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. 1994 Transplant. Proc. pmid:7527961
Gupta S and Brennan DC Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13)-Associated Immune Thrombocytopenic Purpura in a Renal Transplant Recipient: A Case Report. Transplant. Proc. pmid:26915880
Klintmalm GB et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679826
Fukuzawa M and Okada A Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. 1994 Transplant. Proc. pmid:7513483
Jordan ML et al. FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. 1993 Transplant. Proc. pmid:7679827
Warty VS et al. Practical aspects of FK 506 analysis (Pittsburgh experience). 1991 Transplant. Proc. pmid:1721259
Jusko WJ and D'Ambrosio R Monitoring FK 506 concentrations in plasma and whole blood. 1991 Transplant. Proc. pmid:1721260
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Millis JM et al. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. 1996 Transplant. Proc. pmid:8623213
Cai TH et al. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636572
Kim HC and Park SB Mycophenolate mofetil-induced ischemic colitis. 2000 Transplant. Proc. pmid:11119990
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Rodrigo E et al. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus. 2005 Transplant. Proc. pmid:16386549
Favi E et al. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up. 2009 Transplant. Proc. pmid:19460503
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
Klintmalm GB Clinical use of FK 506 in liver transplantation. 1996 Transplant. Proc. pmid:8623484
Goulet O et al. Small bowel transplantation alone or with the liver in children: changes by using FK506. 1998 Transplant. Proc. pmid:9636636
Gerber DA et al. Immunosuppressive agents: recent developments in molecular action and clinical application. 1998 Transplant. Proc. pmid:9636637
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Tojimbara T et al. Oral vs intravenous tacrolimus-based induction therapy in renal transplantation. 1999 Transplant. Proc. pmid:10578282
Nicoluzzi J et al. One hundred pancreas transplants performed in a Brazilian institution. 2009 Transplant. Proc. pmid:20005382
Tryphonopoulos P et al. The impact of Campath 1H induction in adult liver allotransplantation. 2005 Transplant. Proc. pmid:15848669
Tai HC et al. Urachal adenocarcinoma following kidney transplantation: the first case report. 2009 Transplant. Proc. pmid:19545760
Xu M et al. Effect of peritransplant FTY720 alone or in combination with posttransplant FK 506 in a rat model of cardiac allotransplantation. 1997 Transplant. Proc. pmid:9365631
Spada M et al. Monitoring of intestinal myoelectrical activity after isolated small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518141
Yasunami Y et al. Induction of donor-specific unresponsiveness in rat islet allografts by FK 506. 1992 Transplant. Proc. pmid:1376510
Martinez OM et al. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. 1995 Transplant. Proc. pmid:7533372
Motta I et al. FK 506 favors the generation of memory T cells in vitro. 1991 Transplant. Proc. pmid:1721324
Isai H et al. FK 506 and orthotopic liver transplantation in the rat. 1990 Transplant. Proc. pmid:1699329
Daly I et al. Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus. 2002 Transplant. Proc. pmid:12176458
Pascual J et al. Mycophenolate mofetil tolerability and dose changes in tacrolimus-treated renal allograft recipients. 2006 Transplant. Proc. pmid:17097946
Heilman RL et al. Steroid avoidance immunosuppression in low-risk kidney transplant recipients. 2005 Transplant. Proc. pmid:15919466
Krämer BK et al. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens. 2005 Transplant. Proc. pmid:15919467
Kahan BD Current approaches to the use of sirolimus in renal transplantation. 2009 Transplant. Proc. pmid:19857664
Ishikawa T et al. Intestinal function and morphology after ex vivo irradiated small bowel transplantation. 2002 Transplant. Proc. pmid:12034274
Sano N et al. Oral FK 506 blood levels are elevated in pig short bowel model: further investigations with co-administration of an intestinal CYP3A4 inhibitor. 2002 Transplant. Proc. pmid:12034301
Laskow DA et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. 1995 Transplant. Proc. pmid:7533431
Shapiro R et al. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. 1995 Transplant. Proc. pmid:7533432
Reyes J et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721355
Whiteside TL et al. Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721356
Choong CL et al. Dose-Response Relationship Between Diltiazem and Tacrolimus and Its Safety in Renal Transplant Recipients. 2018 Transplant. Proc. pmid:30316389
Shu KH et al. A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan. 1998 Transplant. Proc. pmid:9838570
Bennett WM Renal complications after heart transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083019
Tsuchida T et al. The development of humanized liver with Rag1 knockout rats. 2014 Transplant. Proc. pmid:24815157
Espí A et al. Influence of hepatic ischemia-reperfusion injury on tacrolimus acute renal toxicity in pigs. 2002 Transplant. Proc. pmid:12493373
Aumente Rubio MD et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. 2003 Transplant. Proc. pmid:12962871
Ko S et al. Predominant role of local immunosuppressive effect in enhanced efficacy of liposomal FK506 in organ transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123117
Rao AS et al. Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. 1996 Transplant. Proc. pmid:8908140
Gurkan A et al. Comparison of tacrolimus and neoral-based immunosuppressive regimens in renal transplantation patients: singles-center experience. 2002 Transplant. Proc. pmid:12176525
Kim YI et al. FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. 1994 Transplant. Proc. pmid:7520636
Sanghvi A et al. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. 1989 Transplant. Proc. pmid:2468204
Winkler M et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. 1991 Transplant. Proc. pmid:1721389
Lee HK et al. Expression of Endoplasmic Reticulum-Mediated Stress Proteins in FK506-Treated T-Lymphocytes. 2016 Transplant. Proc. pmid:27320607
Asavakarn S et al. Systematic Pharmaceutical Educational Approach to Enhance Drug Adherence in Liver Transplant Recipients. 2016 Transplant. Proc. pmid:27320587
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. 1999 Feb-Mar Transplant. Proc. pmid:10083507
Elinav H et al. Plasma oxidizability and plasma carbonyls, markers of oxidative stress, in liver transplant patients. 2001 Transplant. Proc. pmid:11543789
Opelz G Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. 1999 Feb-Mar Transplant. Proc. pmid:10083513
Carbajal R et al. Case report: boldo (Peumus boldus) and tacrolimus interaction in a renal transplant patient. 2014 Transplant. Proc. pmid:24981811
Yessayan L et al. Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation. 2015 Transplant. Proc. pmid:26707323
Batten P et al. Effect of cyclosporine A and FK 506 on human T cell responses to xenogeneic and allogeneic endothelium: relative resistance of T cell/porcine endothelial interactions. 1997 Feb-Mar Transplant. Proc. pmid:9123582
Troppmann C et al. FK 506 versus cyclosporine A for steroid-free synergistic combination therapy with rapamycin in a discordant large animal donor xenoislet transplant model. 1997 Feb-Mar Transplant. Proc. pmid:9123585
Nakatani T et al. Effect of tacrolimus on the gene expression of renin and endothelin in the rat kidney. 2001 Transplant. Proc. pmid:11377534
Undre NA and Stevenson PJ Pharmacokinetics of tacrolimus in heart transplantation. 2002 Transplant. Proc. pmid:12176596
Yu X et al. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation. 2008 Transplant. Proc. pmid:19100412
Yuzawa K et al. Topical immunosuppression in skin grafting with FK 506 ointment. 1996 Transplant. Proc. pmid:8658707
Cooper MH et al. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. 1991 Transplant. Proc. pmid:1721419
Yagura K et al. Pharmacokinetic characteristics of two types of liposomal FK 506. 1996 Transplant. Proc. pmid:8658708
Glanemann M et al. Mycophenolate mofetil is superior in combination with tacrolimus compared to cyclosporine for immunosuppressive therapy after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267194
Ju MK et al. Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety. 2013 Transplant. Proc. pmid:23726602
Kohnle M et al. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. 1998 Transplant. Proc. pmid:9723413
Slatinska J et al. Long-term follow-up of stable kidney transplant recipients after conversion from tacrolimus twice daily immediate release to tacrolimus once-daily prolonged release: a large single-center experience. 2013 Transplant. Proc. pmid:23726604
Alessiani M et al. Effect of perioperative donor bone marrow infusion after small bowel transplantation in swine: preliminary results. 1998 Transplant. Proc. pmid:9745496
Aktas S et al. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation. 2011 Transplant. Proc. pmid:21440732
Jelassi ML et al. Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. 2011 Transplant. Proc. pmid:21440742
Arikan C et al. Allergic disease after pediatric liver transplantation with systemic tacrolimus and cyclosporine a therapy. 2003 Transplant. Proc. pmid:14697973
Nikolaidis NL et al. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 1991 Transplant. Proc. pmid:1721450
Abu-Elmagd K et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. 1991 Transplant. Proc. pmid:1721451
Ochiai T et al. Studies on FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450414
Immunosuppression: FK506. 1988 Transplant. Proc. pmid:2450415
Mehra MR et al. Racial differences in clinical outcome using tacrolimus and mycophenolate mofetil immunosuppression in heart transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267442
Yura H et al. Development of a macromolecular prodrug of FK 506: II: In vitro study for FK 506-dextran conjugate. 1998 Transplant. Proc. pmid:9636416
Ikeda M et al. Successful Second Allogeneic Stem Cell Transplantation From a Sibling Donor for Relapse of Myelodysplastic Syndrome in a Recipient of a Renal Transplant From His Mother: Case Report. 2016 Transplant. Proc. pmid:27932152
Filler G Optimization of immunosuppressive drug monitoring in children. 2007 Transplant. Proc. pmid:17524944
Guleria S et al. Tacrolimus (Pan Graf) in live related renal transplantation: an initial experience of 101 recipients in India. 2007 Transplant. Proc. pmid:17445588
Wu J et al. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. 1991 Transplant. Proc. pmid:1703683
Boggi U et al. Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750373
Pillet A et al. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia. 2006 Transplant. Proc. pmid:16980083
Lawen J et al. Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study. 2001 Nov-Dec Transplant. Proc. pmid:11750382
Williams ST et al. Preliminary analysis of a randomized trial comparing microemulsion cyclosporine and tacrolimus for recipients of renal transplants from non-heart-beating donors. 2000 Transplant. Proc. pmid:10701022
Boggi U et al. Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. 2004 Transplant. Proc. pmid:15194369
Anglicheau D et al. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. 2007 Transplant. Proc. pmid:17889118
Copley JB et al. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. 1998 Transplant. Proc. pmid:9636510